Amniotic Products Global Market Report 2024

The amniotic products market size has grown strongly in recent years. It will grow from $0.9 billion in 2023 to $0.98 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The expansion observed in the historic period can be linked to a heightened incidence of burn injuries, a growing recognition of regenerative medicine, an increased utilization of amniotic products in surgical wound care, a rising awareness regarding the efficacy of amniotic products as a viable treatment option, and the global proliferation of amniotic products.

The amniotic products market size is expected to see strong growth in the next few years. It will grow to $1.37 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be associated with the growing preference among patients for non-invasive therapies, an increasing prevalence of chronic wounds, collaborative efforts and partnerships in the healthcare industry, the impact of the COVID-19 pandemic, a rise in the prevalence of ophthalmic disorders, and an overall increase in healthcare expenditure. Major trends expected in the forecast period include the continuous evolution of product technology, strong growth potential, regional dynamics, the lasting impact of COVID-19 and the potential effects of a global recession, an expansion in the target patient population, and emerging economies playing a significant role.

The surge in trauma and accident cases is anticipated to be a driving force behind the burgeoning growth of the amniotic products market. Trauma refers to abrupt and severe physical injuries necessitating urgent medical attention, while accidents encompass unintentional incidents such as slips, vehicular mishaps, or sports injuries. Notably, third-degree burn injuries often necessitate treatment involving full-thickness skin excision combined with a wound dressing composed of a hyper-dry human amniotic membrane. For instance, statistics from the Road Accidents in India 2021 report, published by the Ministry of Road Transport and Highways, an Indian government ministry, indicated a staggering 4,12,432 reported accidents in 2021. Moreover, a report from the National Highway Traffic Safety Administration, a US-based government agency, highlighted 42,915 fatalities resulting from motor vehicle traffic crashes in 2021. These escalating numbers underscore the pivotal role of amniotic products in addressing injuries stemming from trauma and accidents, hence fostering growth in the market.

The escalating demand for surgical interventions is poised to be a significant catalyst propelling the amniotic products market forward. Surgical procedures encompass a range of medical interventions conducted by qualified surgeons to remedy, reconstruct, extract, or substitute a part of the body affected by illness or injury. Amniotic products hold substantial value in surgical procedures, facilitating tissue regeneration, curbing inflammation at surgical sites, expediting recovery, minimizing postoperative discomfort, mitigating pain, and fortifying tissue repair and protection. Noteworthy statistics from the American Society for Metabolic and Bariatric Surgery (ASMBS) in June 2022 underscored that approximately 262,893 bariatric surgeries were performed in 2021. These figures highlight the amplified demand for surgical procedures, thereby fueling the escalating utilization and subsequent growth of amniotic products within the medical landscape.

Innovation stands as a central trend propelling advancements in the amniotic products market. Key industry players are focusing on developing pioneering products to fortify their standing within this competitive landscape. For example, Versea Health Inc., a US-based life science company, introduced Biovance 3L ocular tri-layer human amniotic membrane in November 2022. This product, available in sheet and disc forms, specifically targets surgical and ocular segments. Biovance 3L and Biovance 3L Ocular are tri-layer human amniotic membrane products designed to offer an extracellular matrix for biological membrane covering, fostering healing and tissue growth during wound recovery.

Major companies in the amniotic products market are directing their efforts towards innovative solutions such as dual-layer allografts to drive market growth and bolster revenues. Dual-layer allografts serve patients with complex surgical wounds, burns, and non-healing acute or chronic wounds. For instance, in February 2022, Amnio Technology LLC, a US-based company specializing in amnion-derived technologies, unveiled the palingen dual-layer membrane and dual-layer palingen X-membrane. These advanced allografts target challenging surgical wounds and leverage a dual-layered structure. The design utilizes two Advantek processes, ensuring unidirectional application while preserving the crucial regulatory proteins and extracellular matrix constituents inherent in amniotic tissue. The dual-layer construction and specialized Advantek processes in palingen membranes safeguard the regulatory proteins and extracellular matrix constituents, enhancing their effectiveness in addressing challenging wounds and facilitating tissue repair and regeneration.

In January 2021, Integra LifeSciences, a Canada-based precision medicine company, completed the acquisition of ACell Inc. for an undisclosed amount. This strategic move is part of Integra LifeSciences' initiative to broaden its portfolio of complex wound treatment solutions, leveraging ACell's proprietary MatriStem UBM technologies. ACell Inc., based in the United States, is a biotechnology firm specializing in providing acellular amniotic membrane products.

Major companies operating in the amniotic products market report are Stryker Corporation, Smith & Nephew PLC, Integra LifeSciences Holdings Corporation, Lucina BioSciences LLC, Bioventus LLC, Organogenesis Inc., Alphatec Spine Inc., MiMedx Group, HMP Global, AlloSource, Orthofix US LLC, ACell Inc., Aziyo Biologics Inc., TissueTech Inc., Amino Technology LLC, LifeCell International Pvt. Ltd., Tissue Regenix Group PLC, Aroa Biosurgery Limited, Skye Biologics Inc., Celularity Inc., Sanuwave Health Inc., NuVision Biotherapies Ltd., VIVEX Biologics Inc., Labtician Ophthalmics Inc., Genesis Biologics Inc., Applied Biologics LLC, Katena Products Inc., Next Biosciences, Surgenex LLC, Ventris Medical LLC.

North America was the largest region in the amniotic products market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amniotic products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the amniotic products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of amniotic products include amniotic membranes and amniotic suspensions. Amniotic membranes consist of the innermost layer of the placenta, featuring a robust foundation membrane and an avascular stromal matrix. These membranes find applications in surgical dressing for burns, tissue restoration in oral and bladder procedures, as well as interventions such as tympanoplasty, arthroplasty, omphalocele repair, and prevention of adhesions in pelvic and abdominal surgeries. Amniotic products are utilized across medical specialties, including wound care, orthopedics, ophthalmology, and others, with their deployment occurring in hospitals, ambulatory surgical centers, and similar healthcare settings.

The amniotic products market research report is one of a series of new reports that provides amniotic products market statistics, including amniotic products industry global market size, regional shares, competitors with an amniotic products market share, detailed amniotic products market segments, market trends and opportunities, and any further data you may need to thrive in the amniotic products industry. This amniotic products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The amniotic products market consists of sales of amniotic tissue matrix and amniotic fluid cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.